Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for ESSA Pharma Inc. (EPIX : NSDQ)
 
 • Company Description   
ESSA Pharma Inc. is a pharmaceutical company. The company focused on the development of small molecule drugs for the treatment of cancer, with focus on advanced prostate cancer. ESSA Pharma Inc. is based in Vancouver, Canada.

Number of Employees: 35

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.75 Daily Weekly Monthly
20 Day Moving Average: 49,526 shares
Shares Outstanding: 44.39 (millions)
Market Capitalization: $77.68 (millions)
Beta: 1.56
52 Week High: $7.88
52 Week Low: $1.40
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 2.94% -0.91%
12 Week -2.23% -17.77%
Year To Date -2.23% -8.44%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
999 WEST BROADWAY SUITE 720
-
VANCOUVER,A1 V5Z 1K5
CAN
ph: 778-331-0962
fax: 604-738-4080
essa@argotpartners.com http://www.essapharma.com
 
 • General Corporate Information   
Officers
David Parkinson - President and Chief Executive Officer and Director
Richard M. Glickman - Chairman of the Board
David Wood - Chief Financial Officer (Principal Financial Offic
Marella Thorell - Director
Alex Martin - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 29668H708
SIC: 2834
Fiscal Year
Fiscal Year End: September
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/04/25
Share - Related Items
Shares Outstanding: 44.39
Most Recent Split Date: 4.00 (0.05:1)
Beta: 1.56
Market Capitalization: $77.68 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.31 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.68
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 30.00%
vs. Previous Quarter: 26.32%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -23.48
12/31/24 - -24.61
ROA
06/30/25 - -
03/31/25 - -22.86
12/31/24 - -23.87
Current Ratio
06/30/25 - -
03/31/25 - 67.15
12/31/24 - 33.12
Quick Ratio
06/30/25 - -
03/31/25 - 67.15
12/31/24 - 33.12
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Book Value
06/30/25 - -
03/31/25 - 2.56
12/31/24 - 2.68
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©